Abatacept
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 63 (Table of Contents)
Published: 5 Sep-2005
DOI: 10.3833/pdr.v2005.i63.624 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Abatacept (BR-96 or CTLA4-Ig) is the fi rst biologic discovered internally by Bristol-Myers Squibb (BMS) and, if approved, would be first in a new class of immunosuppressants – selective T-cell costimulation modulators – for the treatment of rheumatoid arthritis (RA)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS